CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 17 enrolled
Drug / intervention
Lithiumdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00703677
NCT00703677Phase 2Completed
CompareCT.gov

A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration

Westat·interventional·Posted Jun 23, 2008·Updated May 17, 2024

In Brief

A Phase 2 clinical trial evaluating Lithium for Progressive Supranuclear Palsy and Corticobasal Degeneration. Completed, enrolled 17 participants across 9 sites in 2 countries.

Detailed Summary

The goal of this trial is to evaluate the safety and tolerability of lithium in people with progressive supranuclear palsy or corticobasal degeneration.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProgressive Supranuclear Palsy, Corticobasal Degeneration
CountriesUnited Kingdom, United States
CollaboratorsNational Institute of Neurological Disorders and Stroke (NINDS)

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 23, 2008
Enrollment StartSep 1, 2008
Primary CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 18.0 years ago

Interventions

Lithiumdrug

All participants will receive lithium. The dosage will be titrated over a 5-week period and then continued for an additional 6 months.